New Insights, New Opportunities,
XinThera Closes $50M Series B Financing
Orbimed Advisors joins existing investors Foresite Capital and TTM Capital, bringing total financing to $80M
Qing Dong, Ph.D., co-founded XinThera in 2021 and serves as its President and CSO. Qing is a passionate drug hunter with more than 20 years of experience in drug discovery. He has particular depth in the structure-based design of oncology and inflammation drug candidates. Qing has contributed to two marketed drugs (Pyrotinib and Fluzoparib) and more than 15 clinical phase compounds. Previously he co-founded small molecule inflammation biotech FronThera in 2015 and served as its President & CSO through its successful acquisition in February 2021. From 2010 to 2015, Qing was CSO at Hengrui and played an integral role in building this leading Chinese pharmaceutical company’s small molecule portfolio. Earlier in his career he worked as a medicinal chemist at both Takeda and Triad Therapeutics. Qing received his Ph.D. in organic chemistry at Rice University in 1995 and his post-doctoral training at Harvard Medical School from 1995-1997.
Stephen Kaldor, Ph.D., co-founded XinThera in 2021 and serves as its Chairman. Steve is a biotech and pharmaceutical industry executive with over 30 years of experience in creating meaningful medicines and shareholder value. He is a co-inventor of three marketed drugs plus multiple other compounds currently in clinical trials. Steve was founding CEO of precision oncology biotech Kinnate Biopharma (NASDAQ: KNTE) from 2018 through 2020 and also served on its Board through 2021. Steve has contributed to other companies including Quanticel (CEO, 2015 acquisition by Celgene), FronThera (strategic advisor, undisclosed 2021 acquisition), Crinetics (Board Member, NASDAQ: CRNX), Furiex (NASDAQ: FURX, Board Member, 2014 acquisition by Forest/Actavis), Amira (Board Member, 2011 acquisition by BMS), Ambrx (CEO & President), and Syrrx (President & CSO, 2005 acquisition by Takeda). He has also advised Foresite Capital, Versant Ventures and Thomas, McNerney and Partners. Steve started his career at Lilly in 1990 and is a chemist by training (Columbia B.A.; Harvard Ph.D.).
Gene Hung, M.D., co-founded XinThera in 2021 and serves as its Senior Vice President Research. He is a seasoned veteran in the field of drug discovery. Previously Gene co-founded small molecule inflammation biotech FronThera in 2015 and served as its Senior Vice President of Biology and Drug Discovery through its successful acquisition in February 2021. He was an executive director at Ionis Pharmaceuticals for over a decade, where he led the drug discovery programs contributing to creating Spinraza, the first drug approved for spinal muscular atrophy (2016), and HTTRx, which advanced to Phase 3 for Huntington's disease. Gene also served as Director at Arena Pharmaceuticals. His prior tenure at House Ear Institute/USC as assistant professor in gene therapy exemplifies his true passion in patient outcome care. Gene obtained his M.D. from Tianjing Medical College, achieved his residency in Tong Ren Hospital, and acquired his Post-Doc at USC. He is a co-inventor on eight patents and a co-author of fifty publications.